Ascendia Pharmaceuticals Revenue and Competitors

North Brunswick, NJ USA

Location

$20M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Ascendia Pharmaceuticals's estimated annual revenue is currently $20.7M per year.(i)
  • Ascendia Pharmaceuticals's estimated revenue per employee is $201,000
  • Ascendia Pharmaceuticals's total funding is $20M.

Employee Data

  • Ascendia Pharmaceuticals has 103 Employees.(i)
  • Ascendia Pharmaceuticals grew their employee count by 1% last year.

Ascendia Pharmaceuticals's People

NameTitleEmail/Phone
1
SVP Business DevelopmentReveal Email/Phone
2
Director Engineering and FacilitiesReveal Email/Phone
3
Chief Business OfficerReveal Email/Phone
4
Director Business DevelopmentReveal Email/Phone
5
Senior DirectorReveal Email/Phone
6
Senior Director Business DevelopmentReveal Email/Phone
7
Senior Formulation ScientistReveal Email/Phone
8
Senior ScientistReveal Email/Phone
9
Senior ScientistReveal Email/Phone
10
Senior Director Business DevelopmentReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$6.6M3332%N/AN/A
#2
$38M1896%N/AN/A
#3
$6.6M3322%N/AN/A
#4
$4180M152421%$550MN/A
#5
$17.5M8750%N/AN/A
#6
$6.7M125-37%$199.6MN/A
#7
$10.9M5415%N/AN/A
#8
$15.3M7633%N/AN/A
#9
$128.6M64016%N/AN/A
#10
$18.7M9321%N/AN/A
Add Company

What Is Ascendia Pharmaceuticals?

Based in North Brunswick, New Jersey, Ascendia Pharmaceuticals is a specialty contract development and manufacturing (CDMO) company dedicated to delivering sophisticated formulations of existing drug products, and enabling formulations for preclinical- and clinical-stage drug candidates. Ascendia Pharmaceuticals is your ideal partner for: · Early stage IND-enabling formulations for toxicology and pharmacokinetic (PK) studies · Rapid development through Phase I CTM materials for oral and parenteral dosage forms · Fast discovery formulation support · Formulation development and CTM manufacturing for specialty pharmaceuticals Ascendia Pharmaceuticals also provides special development programs: · Formulations for poorly soluble and low bioavailability drugs · First-in-man injectable formulations · Nano-emulsion and nano-particle formulations · Peptide formulations · Sustained release by parenteral or oral routes · Development of 505(b)(2) products · Development of complex generics · High potency and DEA controlled drug substances · Ocular formulation development · Animal health formulations

keywords:N/A

$20M

Total Funding

103

Number of Employees

$20.7M

Revenue (est)

1%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.5M11215%N/A
#2
$16.2M112-3%N/A
#3
$16.5M114-27%N/A
#4
$30.8M1141%N/A
#5
$17.5M1213%N/A